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Background: Surgical lung biopsy (SLB) is generally considered to be the most appropriate method for 
diagnosing diffuse lung disease. However there are few reports focusing only on the same thoracoscopic 
technique. This study was designed to determine the morbidity and mortality related to video-assisted 
thoracoscopic lung biopsy (VTLB) in a single center, thereby providing data on the evaluated severity of 
morbidity and clarifying risk factors. 
Methods: We analyzed 285 patients with undiagnosed diffuse lung disease underwent VTLB at Kanagawa 
Cardiovascular and Respiratory Center from February 2007 to April 2012. We classified the severities of 
postoperative complications based on the Clavien-Dindo classification.  
Results: The surgical morbidity rate was 7.0% (20/285). Twenty patients experienced morbidities, including 
delayed pulmonary fistulas in 11, acute exacerbation (AE) in 3, prolonged air leakage (>7 days) in 2, 
hypoxemia in 2, atrial fibrillation in 1, and premature ventricular contraction in 1. Based on the Clavien-
Dindo classification, grade I, II, IIIa, IIIb, IVa complications accounted for 20%, 10%, 50%, 5%, and 15%, 
respectively. The 30-day mortality rate was 0%. The diagnostic yield was 100%. Although AE occurred in 2 
patient with idiopathic pulmonary fibrosis (IPF) and 1 with fibrotic nonspecific interstitial pneumonia 
(fNSIP), there were no distinctive features that allowed preoperative prediction of AE.  
Conclusions: The morbidity rate was 7% and the mortality rate was 0% among patients with diffuse lung 
disease who underwent the same VTLB technique in this study, indicating that VTLB is a feasible procedure. 
We hope to clarify risk factors in future research. 
 
Key words: surgical lung biopsy (SLB), video-assisted thoracoscopic lung biopsy (VTLB), Clavien-Dindo 







Surgical lung biopsy (SLB) is generally considered to be the most appropriate method for diagnosing diffuse 
lung disease [1,2]. SLB is recommended for patients with clinically undiagnosed conditions, but that are 
suggestive of interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF) [3]. SLB alters 
treatment in many patients who have undergone this examination, resulting in improvement of their clinical 
symptoms [2,4]. Most previous studies on SLB included cases of open lung biopsy and video-assisted 
thoracoscopic lung biopsy (VTLB) as well, and there are few reports focusing only on the same 
thoracoscopic technique [2,4-7]. Even reports dedicated to video-assisted thoracoscopic surgery (VATS) 
alone have not provided details of the surgery [8]. Although the incidence of complications of SLB is 
reported to be 6-25%, the evaluated severities and outcomes of these complications have not yet been 
reported in detail [2,4,6,9]. The Clavien-Dindo classification is widely used these days as an objective 
method of classifying complication severity [10,11]. We used this classification in the present study. 
Although acute exacerbation (AE) is currently recognized as a complication that is not rare and is associated 
with a high mortality rate, no definite risk factors have been demonstrated [12,13]. This study was designed 
to determine the morbidity and mortality related to VTLB in a single center, thereby providing data on the 
evaluated severity of morbidity and clarifying risk factors. 
 
Material and Methods 
This was a retrospective study. Because individual patients were not identified, our institutional review board 
waived the requirement for obtaining patient consent and approved this study. From February 2007 to April 
2012, a total of 313 patients with undiagnosed diffuse lung disease underwent SLB at Kanagawa 
Cardiovascular and Respiratory Center for the purpose of tissue diagnosis. The inclusion criteria were as 
follows:, (1) male or female patients aged 18 - 85 years, (2) without a pathological diagnosis by biopsies such 
as transbronchial lung biopsy, (3) clinical course or radiographic findings were not typical of IPF, (4) 
performance status (PS) of 2 or less, (5) no remarkable decrease in respiratory function, (6) no serious or 
4 
 
uncontrolled comorbidities. Under these criteria, we considered surgical indications at a joint conference of 
pulmonologists, radiologists, and thoracic surgeons. We excluded from the analysis 28 patients who 
underwent simultaneous lymph node biopsy and bullectomy. Finally, we analyzed 285 patients. The medical 
records of all patients were retrospectively reviewed. Data gathered included age at the time of biopsy, 
gender, smoking status, comorbidities, preoperative corticosteroid use, preoperative O2 dependence, 
laboratory findings, preoperative pulmonary function, arterial blood gases, demographic information, 
indications for biopsy, definitive diagnosis, perioperative morbidity, and mortality. High-resolution computed 
tomography (HRCT) data were available in all patients. We selected the biopsy site in consultation with a 
pulmonologist (T.O.) on the basis of chest HRCT findings, and then indicated this site with a marker on the 
HRCT films. Intraoperatively, we considered the properties of the resected lung, and then made a final 
determination. We left the electrocardiographic monitor in place until postoperative day 1. 
SLB was performed under general anesthesia with one lung ventilated using a double-lumen endotracheal 
tube in a full lateral position. The surgical procedure remained consistent throughout the study period. A 5-
mm videothoracoscope was used and three access ports (5-, 5- and 10-mm diameters) were positioned. An 
endo-stapler was used to perform the wedge resection. The mean number of samples was 2.0, with one 
generally taken from the transition zone between normal and diseased lung and the other from a site of active 
disease. All patients were extubated at the end of the surgical procedure. Postoperatively, we did not 
administer prophylaxis, such as steroids, immunosuppressants or neutrophil elastase inhibitors, for AE. We 
classified the severities of postoperative complications based on the Clavien-Dindo classification (Table 1) 
[11]. Postoperative AE was defined according to previous reports and the revised criteria for AE of IPF in 
Japan (see appendices in online supplementary material) [14,15]: within 14 postoperative days, (1) subjective 
worsening of dyspnea, (2) new ground-glass opacities or consolidation on chest radiograph or HRCT, (3) 
decrease in arterial oxygen tension (PaO2) of more than 10 mmHg under similar conditions, (4) absence of 
apparent infection and heart failure. 
All biopsy specimens were swabbed for cultures, and then gently inflated with formalin, using a syringe and 
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needle. The specimens were dehydrated and embedded in paraffin. Sections were routinely stained with 
hematoxylin and eosin. Biopsy slides were reviewed independently by at least two pathologists (K.O. and 
T.T.) and classified according to the American Thoracic Society/European Respiratory Society consensus 
classification of interstitial pneumonia [16].  
Data are expressed as median values with ranges for continuous variables, and number (percentages for 
categorical variables). All analyses were performed using statistical software (IBM SPSS Statistics 20; IBM 
Corp.; Armonk, NY, USA). 
 
Results 
The clinical characteristics of all 285 patients are summarized in Table 2. The patient population consisted of 
161 men (56.5%) and 124 women (43.5%), with a median age at the time of biopsy of 65 years (range, 18-85 
years). There were 36 current smokers (12.6%), 133 ex-smokers (46.7%), and 116 never smokers (40.7%). 
The median smoking index was 230 (range, 0-3000). At the time of SLB, 19 patients (6.7%) received 
corticosteroid therapy and 14 (4.9%) required supplemental oxygen therapy. Before SLB, 201 patients 
(70.5%) had undergone fiber bronchoscope/bronchoalveolar lavage (BAL), but no definitive diagnosis could 
be obtained. No patients had human immunodeficiency virus infection or active cancer. Median Krebs von 
den Lungen-6 (KL-6) was 947 (range, 170-7696) U/mL. Median operating and anesthesia times were 63 
minutes (range, 34-252 minutes) and 119 minutes (range, 79-315 minutes), respectively. Adhesion between 
the lung and chest wall was seen in 58 patients (20.4%), partial in 49, and severe in 9. One case with dense 
pleural adhesions required conversion to minithoracotomy. In 13 patients, we added a 5-mm port. The 
number of biopsy sites was 1 in 16 patients, 2 in 244, and 3 in 25. The median duration of chest drainage was 
1 day (range, 1-13 days). 
The surgical morbidity rate was 7.0% (20/285). Twenty patients experienced morbidities, including delayed 
pulmonary fistulas in 11, AE in 3, prolonged air leakage (>7 days) in 2, hypoxemia in 2, atrial fibrillation in 
1, and premature ventricular contraction in 1 (Table 3). Based on the Clavien-Dindo classification, the 11 
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patients with delayed pulmonary fistulas consisted of 3 as grade I (improvement with follow-up alone) and 8 
as grade IIIa (requiring chest drainage). None of these patients required pleurodesis or reoperation. As for 
AE, all 3 patients were classified as grade IVa. Two patients received medical treatment, including high-dose 
systemic corticosteroid therapy (methylprednisolone, 500 mg/day for 3 days) followed by tapering of the 
dose and immunosuppressants, in our intensive care unit. The remaining patient also received medical 
treatment in an intensive care unit, although the details were unknown, because the treatment was given at 
another hospital. Prolonged air leakage (>7 days) in 2 patients resolved with continuing drainage (grade IIIa), 
although the hospital stay was extended. Hypoxemia in 2 patients required home oxygen therapy (grade II). 
Atrial fibrillation classified as grade IIIb occurred in the operating room just after SLB, but sinus rhythm was 
restored defibrillation. Premature ventricular contraction did not require medication (grade I). Grade I, II, 
IIIa, IIIb, IVa complications accounted for 20%, 10%, 50%, 5%, and 15%, respectively. 
The 30-day mortality rate was 0%. The diagnostic yield was 100%. The pathologic diagnosis after SLB was 
idiopathic interstitial pneumonias (IIPs) in 169 patients (59.3%), interstitial pneumonia associated with 
collagen vascular disease (CVD-IP) in 47 (16.5%), chronic hypersensitivity pneumonitis (CHP) in 29 
(10.2%), lymphoproliferative disorders (LPD) in 14 (4.9%), and others in 26 (9.1%) (Table 4). We shows 
typical histopathological findings of IPF in Figure. Among the 169 patients with IIPs, 60 had a diagnosis of 
IPF, and 60 had nonspecific interstitial pneumonia (NSIP), consisting of 52 with fibrotic NSIP (fNSIP) and 7 
with cellular NSIP. The lung tissues obtained by SLB were also cultured, but yielded no specific findings. 
AE occurred in two 67-year-old men and one 76-year-old woman on postoperative days 6, 12, and 14, 
respectively. Table 5 presents a comparison of clinical features between patients with and without AE. The 
non-exacerbation group consisted of 169 patients with IIPs, 47 with CVD-IP, and 29 with CHP. Patients with 
other diseases were excluded from the non-exacerbation group because there are no reports of AE in such 
cases. AE occurred in 2 of 60 (3.3%) IPF patients and, in 1 of 52 (1.9%) fNSIP patients. Two of these patients 
were ex-smokers and one had never smoked. No patients received corticosteroid therapy or required 
supplemental oxygen therapy. None of the patients had clinical evidence of apparent infection or heart 
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failure. None of these patients had shown an accelerated decline before SLB. SLB, BAL, or spirometry had 
not been performed at the time of AE, because iatrogenic procedures can induce, aggravate, or accelerate 
worsening of respiratory conditions. Although all 3 patients survived to discharge from the hospital, 2 later 
died from disease progression 3 months and 4 months after discharge, respectively. The remaining patient has 
survived 41 months, to date. 
 
Discussion 
In this study, we retrospectively reviewed patients with diffuse lung disease who underwent VTLB in our 
institution. VTLB reportedly reduces the mortality rate and the length of hospital stay [7]. VTLB was safe for 
diagnosing UIP, with no short-term mortality, although open-lung biopsy was followed by 5.3% of patients 
within 1 month after procedure [7]. The morbidity rate was 2.9% (1/34) in VTLB group and 14.3% (6/42) in 
open-lung biopsy group [7]. On the other hand, the only randomized controlled trial of SLB for interstitial 
lung disease, reported by Miller et al. in 2000, revealed no statistically significant differences in outcomes, 
such as length of hospital stay, complications, and total morphine dose, between patients who underwent 
thoracoscopy (20 patients) and those underwent limited thoracotomy (22 patients) [1,17]. Four major 
complications occurred in each group. Definitive pathologic diagnoses were made in both groups [17]. 
However, the study by Miller et al. dealt with a limited number of patients, and the thoracoscopic method 
was left to the discretion of the surgeon in charge. Most previous reports on SLB included a mixture of cases 
with open lung biopsy and VTLB because of the long study periods [2,4-7]. In contrast, we focused only on 
cases of VTLB performed by the same technique in a single center. In addition, in order to exclude the 
influences of other procedures such as lymph node biopsy, the subjects of this study were restricted to 
patients who underwent lung biopsy alone. The morbidity rate (7.0%) in this study was not inferior to 
previous reports. In our institution, we apply SLB criteria to select appropriate candidates for SLB, and are 
making efforts to avoid the implementation of unnecessary SLB by holding joint conferences. Our institution 
has a respiratory disease specialist who is an expert on interstitial lung disease. Because of this, many 
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patients are referred to our institution from neighboring hospitals, and therefore the number of our SLB cases 
is high, being the largest such patient population in Japan. 
 We used a 3-port complete thoracoscopic approach. None of our patients were unable to tolerate 
one-lung ventilation and none required conversion to minithoracotomy. Although adhesions were found in 
20% (58/258) of patients, conversion to minithoracotomy occurred in only one. Biopsy specimens were 
obtained from at least 2 sites in 94% (269/285) of patients. Because sufficient quantities of tissue were 
obtained, the diagnostic yield was 100%. 
 In this study, we used the Clavien-Dindo classification for evaluation of the severities of 
complications. The Clavien-Dindo classification, that was proposed in 1992 and revised in 2004, has to date 
been serving as an objective method of classifying the severities of complications related to surgery [10,11]. 
Its reproducibility and validity were demonstrated by a large-scale cohort study. This classification is 
currently used worldwide in all areas of surgery, with its usefulness being demonstrated in the field of 
thoracic surgery as well. The present report is the first to focus on complications of SLB determined based on 
the Clavien-Dingo classification. The percentage of major complications at grade III/IV was 70%, whereas 
that for minor complications at grade I/II was 30%. Thus, the incidence of complications after SLB requiring 
intervention was high. Delayed pulmonary fistula often required chest drainage, highlighting the necessity of 
careful postoperative follow-up by chest radiography. 
 A diagnosis was established in all 285 SLB cases, and there were no deaths related to the 
procedure. Our VTLB can be considered as a safe and useful procedure, comparing with previous reports. 
The incidence rate of AE was low. Although postoperative AE occurred in 3 (1.1%) patients, all recovered to 
discharge. It is said that the annual incidence of AE is about 5-10% during the natural course of IPF [12], and 
AE reportedly occurred in 2.4% of patients with IPF who underwent BAL [18]. Kondoh et al. reported that 
postoperative AE occurred in 5 (2.5%) of 236 patients with diffuse lung disease who underwent SLB [6]. The 
low incidence of AE in our present study is presumably attributable to the small total number of patients or 
the scarcity of patients with severe progressive interstitial lung disease. Although any type of fibrosing 
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chronic interstitial lung disease can cause AE, clinical data are limited as to AE in interstitial lung diseases 
other than IPF, e.g., NSIP [19,20]. Park et al. found that the annual incidence of AE was 4.2% among patients 
with idiopathic NSIP not accompanied by collagen disease, but they reported a favorable prognosis [19]. 
Yano et al. studied patients with lung cancer accompanied by interstitial pneumonia who underwent surgical 
resection, and reported that AE occurred in 1 of 7 patients with IPF and 4 of 25 with fNSIP [20]. Although 
further accumulation of data is important, caution regarding AE may be necessary in patients with fNSIP, as 
it is in those with IPF. 
 Although there are many reports on postoperative AE, no risk factors have as yet been established 
[12,13]. In this study, patients with AE tended to have the following features: advanced age, prolonged 
operation and anesthesia, high values of KL-6 and surfactant protein D (SP-D), and low vital capacity (% 
predicted) and forced vital capacity (% predicted). However, there were no distinctive features that allowed 
preoperative prediction of AE (Table 5). Careful follow-up with the possibility of postoperative AE in mind is 
warranted in all patients with chronic interstitial lung disease that shows fibrosis on computed tomography. 
Our institution does not adopt aggressive application of perioperative prophylactic medication for AE, 
because sufficient evidence of its efficacy is lacking. 
 The limitations of this study include the rarity of AE events, which precluded appropriate statistical 
processing, and selection bias. Although AE has become widely recognized, its occurrence in relation to 
minimally invasive VTLB is low. In addition, we set a strict criterion for AE occurrence within 14 
postoperative days in this study because our goal was to identify direct influences of VTLB. Although the 
number of VTLB cases was greater in this study than in any other previous investigation of its kind, the 
number of AE events was very low. Some potential subjects with advanced disease might have been excluded 
from among the candidates for SLB by the pulmonologist who examined the patients at presentation, 
representing a selection bias. It is hoped that a future multicenter randomized controlled trial will clarify the 
risk factors for AE. 
 In conclusion, the morbidity rate was 7% and the mortality rate was 0% among patients with 
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diffuse lung disease who underwent the same VTLB technique in this study, indicating that VTLB is a 
feasible procedure. Our procedure is recommended for operable patients with clinically undiagnosed 
conditions, but that clinical course or radiographic findings were not typical of IPF. Based on the Clavien-
Dindo classification for evaluating the severities of complications, grade III/IV complications requiring some 
form of intervention occurred in 70% of cases, but improvement was achieved in all of these cases. Although 
AE occurred in 2 patient with IPF and 1 with fNSIP, there were no distinctive features allowing the 
prediction of AE preoperatively. We hope to clarify risk factors in future research. 
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Any deviation from the normal postoperative course without the need for
pharmacological treatment or surgical, endoscopic and radiological interventions
Grade II Requiring pharmacological treatment with drugs
Grade III Requiring surgical, endoscopic or radiological intervention
  Grade IIIa Intervention not under general anesthesia
  Grade IIIb Intervention under general anesthesia
Grade IV Life-threatening complication requiring intensive care unit management
  Grade IVa Single organ dysfunction
  Grade IVb Multi organ dysfunction
Grade V Death of the patient
Table 1. Classification of postoperative complications based on the Clavien-Dindo
classification
Age (years) 18-85, median 65
Gender (Men/Women) 161/124
Smoking status (Current/ex-smoker/never) 36/133/116
Smoking index 0-3000, median 230
Comorbidities 203 (71.2%)
Pre-op corticosteroid therapy 19 (6.7%)
Pre-op O2 dependence 14 (4.9%)
BAL 201 (70.5%)
KL-6 (U/mL) 170-7696, median 947
PaO2 (mmHg) 52.1-128.9, median 81.4
VC, % predicted 42.0-178.8, median 84.9
FEV1.0, % predicted 39.8-147.0, median 81.1
FVC, % predicted 40.9-154.0, median 83.7
DLCO, % predicted 30.6-198.0, median 79.0
Operating time (min) 34-252, median 63
Anesthesia time (min) 79-315, median 119
Blood loss (ml) 0-100. median 5
Adhesion (partial/severe) 49/9
Convert to minithoracotomy 1 (0.4%)
Biopsy sites (1/2/3) 16/244/25
Chest drainage (day) 1-13, median 1
Morbidity 20 (7.0%)
The 30-day mortality 0%
Diagnostic yield 100%
Table 2. Clinical characteristics - 285 patients
BAL: bronchoalveolar lavage, KL-6: Krebs von den Lungen-6, PaO2: arterial
oxygen tension, VC: vital capacity, FEV1.0: forced expiratory volume in 1 second,
FVC: forced vital capacity, DLCO: carbon monoxide diffusing capacity of the










Total I II IIIa IIIb IVa IVb V
Delayed pulmonary fistulas 11 (100) 3 (27) 0 (0) 8 (73) 0 (0) 0 (0) 0 (0) 0 (0)
Acute exacerbation 3 (100) 0 (0) 0 (0) 0 (0) 0 (0) 3 (100) 0 (0) 0 (0)
Prolonged air leakage (>7 days) 2 (100) 0 (0) 0 (0) 2 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Hypoxemia 2 (100) 0 (0) 2 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Atrial fibrillation 1 (100) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 0 (0)
Premature ventricular contraction 1 (100) 1 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 20 (100) 4 (20) 2 (10) 10 (50) 1 (5) 3 (15) 0 (0) 0 (0)
Complications
Table 3. Evaluation of the severity of postoperative complications based on the Clavien-Dindo classification
Grades (%)
Idiopathic interstitial pneumonias (IIPs) 169
  Idiopathic pulmonary fibrosis (IPF) 60
  Nonspecific interstitial pneumonias (NSIP) 60
    fibrotic nonspecific interstitial pneumonias (fNSIP) 52
    cellular nonspecific interstitial pneumonias (cNSIP) 7
  Cryptogenic organizing pneumonia (COP) 4
  Acute interstitial pneumonia (AIP) 1
  Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) 1
  unclassified 43
Interstitial pneumonia associated with collagen vascular disease (CVD-IP) 47
Chronic hypersensitivity pneumonitis (CHP) 29
Lymphoproliferative disorders (LPD) 14
Summer-type hypersensitivity pneumonitis (SHP) 4
Pneumoconiocis 4




Idiopathic pulmonary upper lobe fibrosis 1
Langerhans cell histiocytosis 1





Other granulomatous disease 1
Others 2
total 285










Age (yr) 67 (67-76) 65 (64-67)
Operating time (min) 72 (69-81) 62 (60-65)
Anesthesia time (min) 135 (105-150) 118 (115-123)
LDH (IU/L) 237 (200-262) 245 (238-250)
CRP (mg/dL) 0.20 (0.10-0.37) 0.15 (0.13-0.18)
KL-6 (U/mL) 1451 (1058-1470) 1015.5 (919-1130)
SP-D (ng/mL) 325 (184-591) 186 (175-207)
PaO2 (mmHg) 80.3 (75.9-92.2) 81.4 (80.1-83.0)
VC, % predicted 62.7 (59.7-78.9) 84.8 (81.9-87.1)
FEV1.0, % predicted 82.9 (70.9-83.7) 80.8 (79.9-81.9)
FVC, % predicted 64.1 (54.4-76.2) 83.1 (78.6-86.7)
DLCO, % predicted 93.2 (52.4-101.6) 78.4 (75.0-81.8)
LDH: lactate dehydrogenase, CRP: C-reactive protein, KL-6: Krebs von den Lungen-6, SP-D:
surfactant protein D, PaO2: arterial oxygen tension, VC: vital capacity, FEV1.0: forced
expiratory volume in 1 second, FVC: forced vital capacity, DLCO: carbon monoxide diffusing
capacity of the lung, Values given as median (95% confidence interval).
Table 5. Comparison of clinical features between patients with and without acute exacerbation
